Recent EVAX News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/12/2026 01:30:05 PM
- Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress • GlobeNewswire Inc. • 05/12/2026 01:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/07/2026 11:40:05 AM
- Evaxion announces business update and first quarter 2026 financial results • GlobeNewswire Inc. • 05/07/2026 11:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/04/2026 12:07:38 PM
- Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026 • GlobeNewswire Inc. • 05/04/2026 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/27/2026 12:10:07 PM
- Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer • GlobeNewswire Inc. • 04/27/2026 12:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 09:19:52 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/22/2026 11:00:08 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/17/2026 07:30:06 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/17/2026 07:20:06 PM
- Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial • GlobeNewswire Inc. • 04/17/2026 07:10:00 PM
- New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma • GlobeNewswire Inc. • 04/17/2026 07:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/16/2026 04:00:14 PM
- Evaxion concludes Annual General Meeting • GlobeNewswire Inc. • 04/16/2026 03:30:00 PM
- Form 3/A - Initial statement of beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 04/10/2026 08:20:54 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/07/2026 12:05:06 PM
- Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01 • GlobeNewswire Inc. • 04/07/2026 12:00:00 PM
- Form 3/A - Initial statement of beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 04/02/2026 08:06:38 PM
- Form 3/A - Initial statement of beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 04/02/2026 12:55:35 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/30/2026 12:05:06 PM
- Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress • GlobeNewswire Inc. • 03/30/2026 12:00:00 PM
- Form 3/A - Initial statement of beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 03/27/2026 09:09:43 PM
- Form 3/A - Initial statement of beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 03/27/2026 09:09:14 PM
